ArticleNeurology2020
Characterizing opioid use in a US population with migraine: Results from the CaMEO study.
Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07633067 (Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine: A Multicenter, Prospective, Double-blind, Multigroup, Randomized Controlled Trial.
Who cites it
27 citing papers in PubMed, 73 citations in OpenAlex.
- Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial.The journal of headache and pain · 2026Trial
- Persistent headache after aneurysmal subarachnoid hemorrhage: Prevalence, characteristics, and migraine history as a prognostic factor.Headache · 2026Article
- Mitochondrial dysfunction in the spinal cord contributes to peripheral hypersensitivity in a nitroglycerin-induced migraine model.Journal of translational medicine · 2026Article
- Do patients with migraine and obesity receive different treatments? Insights from real-world data.Headache · 2026Article
- Opioid Use among People with Migraine: Results of the OVERCOME (US) Study.Pain and therapy · 2025Article
- Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine.Pain and therapy · 2025Review
- Fitness-to-work considerations in the paradigmatic pain condition of headache disorder.The journal of headache and pain · 2025Review
- From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder.British journal of clinical pharmacology · 2024Review
- Intergroup time bias and aversive racism in the medical context.Journal of personality and social psychology · 2024Article
- Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis.The journal of headache and pain · 2024Article
- Migraine Prevalence, Environmental Risk, and Comorbidities in Men and Women Veterans.JAMA network open · 2024Article
- Rethinking headache as a global public health case model for reaching the SDG 3 HEALTH by 2030.The journal of headache and pain · 2023Review
- Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review.Neurology and therapy · 2023Review
- Potentially Inappropriate Use of Opioids in the Management of Migraine in Colombia.Biomedicines · 2023Article
- Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China.Pain and therapy · 2023Article
- PACAP-PAC1 receptor inhibition is effective in opioid induced hyperalgesia and medication overuse headache models.iScience · 2023Article
- Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression.Journal of managed care & specialty pharmacy · 2022Article
- Addressing the cost of chronic and episodic migraine and its main drivers: a short-term longitudinal analysis from a third-level Italian center.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research.Pharmaceutical medicine · 2022Observational
- Association between patent foramen ovale and migraine without aura: a community-based cross-sectional study in China.BMJ open · 2022Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the prevalence of and risk factors associated with opioid use in the treatment of migraine, we examined demographics and clinical characteristics of 867 individuals who reported using opioids for the treatment of migraine.
methodsWe analyzed data from the CaMEO study (Chronic Migraine Epidemiology and Outcomes), a cross-sectional, longitudinal, Internet study, to compare sociodemographics, clinical characteristics, and migraine burden/disability of opioid users vs nonusers. Covariates were entered as categorical or continuous variables. Factors associated with opioid use were identified using nested, multivariable binary logistic regression models.
resultsOf 2,388 respondents with migraine using prescription medications for acute treatment, 36.3% reported that they currently used or kept on hand opioid medications to treat headaches. Current opioid users had significantly more comorbidities, greater headache-related burden, and poorer quality of life than nonusers. Regression models revealed factors significantly associated with opioid use, including male sex, body mass index, allodynia, increasing monthly headache frequency, Total Pain Index score (excluding head, face, neck/shoulder), anxiety, depression, ≥1 cardiovascular comorbidity, and emergency department/urgent care use for headache in the past 6 months. Self-reported physician-diagnosed migraine/chronic migraine was associated with significantly decreased likelihood of opioid use.
conclusionsOf respondents who were using acute prescription medications for migraine, more than one-third used or kept opioids on hand, contrary to guidance. This analysis could not distinguish risk factors from consequences of opioid use; thus further research is needed to guide the development of strategies for reducing the inappropriate use of opioids in migraine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.